{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:27:55Z","timestamp":1787686075160,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11255-021-02965-w","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T14:02:27Z","timestamp":1628949747000},"page":"1079-1084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability"],"prefix":"10.1007","volume":"54","author":[{"given":"Miwa","family":"Masumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kuragano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisa","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ookawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Yahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arithoshi","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayshi","family":"Nanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"issue":"1","key":"2965_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","volume":"61","author":"I Koulouridis","year":"2013","unstructured":"Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL (2013) Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a meta-regression analysis. Am J Kidney Dis 61(1):44\u201356","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2965_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/ki.2014.114","volume":"86","author":"T Kuragano","year":"2014","unstructured":"Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T et al (2014) Association between hemoglobin variability, serum ferritin levels, and adverse events\/mortality in maintenance hemodialysis patients. Kidney Int 86(4):845\u2013854","journal-title":"Kidney Int"},{"key":"2965_CR3","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ki.1995.354","volume":"48","author":"MF Hand","year":"1995","unstructured":"Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ (1995) Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48:806\u2013813","journal-title":"Kidney Int"},{"key":"2965_CR4","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1681\/ASN.V1071440","volume":"10","author":"E Brochu","year":"1999","unstructured":"Brochu E, Lacasse S, Larivi\u00e8re R, Kingma I, Grose JH, Lebel M (1999) Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 10:1440\u20131446","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2965_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/ndt\/gfx269","volume":"33","author":"R P\u00e9rez-Garc\u00eda","year":"2018","unstructured":"P\u00e9rez-Garc\u00eda R, Varas J, Cives A, Mart\u00edn-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI, ORD group (2018) Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant 33(4):690\u2013699","journal-title":"Nephrol Dial Transplant"},{"key":"2965_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.ajkd.2008.12.030","volume":"53","author":"ND Vaziri","year":"2009","unstructured":"Vaziri ND (2009) Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency. Am J Kidney Dis 53:733\u2013736","journal-title":"Am J Kidney Dis"},{"key":"2965_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jcp.2010.086991","volume":"64","author":"M Munoz","year":"2011","unstructured":"Munoz M, Garcia-Erce JA, Remacha AF (2011) Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 64:287\u2013296","journal-title":"J Clin Pathol"},{"key":"2965_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMra1004967","volume":"366","author":"RE Fleming","year":"2012","unstructured":"Fleming RE, Ponka P (2012) Iron overload in human disease. N Engl J Med 366:348\u2013359","journal-title":"N Engl J Med"},{"issue":"1","key":"2965_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ki.2014.275","volume":"87","author":"GR Bailie","year":"2015","unstructured":"Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B et al (2015) Data from the Dialysis Outcomes and Practice Patterns Study validate an association between intravenous iron doses and mortality. Kidney Int 87(1):162\u2013168","journal-title":"Kidney Int"},{"issue":"5","key":"2965_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12185-014-1554-6","volume":"99","author":"Y Sasaki","year":"2014","unstructured":"Sasaki Y, Noguchi-Sasaki M, Matsuo-Tezuka Y, Matsumoto-Omori Y, Kurasawa M, Yorozu K et al (2014) Epoetin Beta Pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol 99(5):561\u2013569","journal-title":"Int J Hematol"},{"issue":"3","key":"2965_CR11","first-page":"240","volume":"14","author":"Japanese Society for Dialysis Therapy","year":"2018","unstructured":"Japanese Society for Dialysis Therapy (2018) Guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14(3):240\u2013275","journal-title":"Ther Apher Dial"},{"issue":"5704","key":"2965_CR12","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM et al (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704):2090\u20132093","journal-title":"Science"},{"key":"2965_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000380967","volume":"185","author":"T Nakanishi","year":"2015","unstructured":"Nakanishi T, Hasuike Y, Otaki Y, Nanami M, Kuragano T (2015) Dysregulated iron metabolism in patients on hemodialysis. Contrib Nephrol 185:22\u201331","journal-title":"Contrib Nephrol"},{"issue":"2","key":"2965_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","volume":"36","author":"T Ganz","year":"2016","unstructured":"Ganz T, Nemeth E (2016) Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol 36(2):87\u201393","journal-title":"Semin Nephrol"},{"issue":"6","key":"2965_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000312381","volume":"31","author":"T Kuragano","year":"2010","unstructured":"Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y et al (2010) Determinants of hepcidin in patients on maintenance hemodialysis: role of Inflammation. Am J Nephrol 31(6):534\u2013540","journal-title":"Am J Nephrol"},{"issue":"7","key":"2965_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46(7):678\u2013684","journal-title":"Nat Genet"},{"issue":"5","key":"2965_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/1744-9987.12161","volume":"18","author":"M Kakimoto-Shino","year":"2014","unstructured":"Kakimoto-Shino M, Toya Y, Kuji T, Fujikawa T, Umemura S (2014) Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Ther Apher Dial 18(5):421\u2013426","journal-title":"Ther Apher Dial"},{"issue":"1","key":"2965_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12185-017-2215-3","volume":"106","author":"Y Matsuo-Tezuka","year":"2017","unstructured":"Matsuo-Tezuka Y, Noguchi-Sasaki M, Kurasawa M, Yorozu K, Shimonaka Y (2017) The effect of frequency of C.E.R.A. administration on the contribution of dietary iron for erythropoiesis. Int J Hematol 106(1):60\u201370","journal-title":"Int J Hematol"},{"issue":"3","key":"2965_CR19","doi-asserted-by":"publisher","first-page":"e0147328","DOI":"10.1371\/journal.pone.0147328","volume":"11","author":"T Kuragano","year":"2016","unstructured":"Kuragano T, Kitamura K, Matsumura O, Matsuda A, Hara T, Kiyomoto H et al (2016) ESA hyporesponsiveness is associated with adverse events in maintenance hemodialysis (MHD) patients, but not with iron storage. PLoS ONE 11(3):e0147328","journal-title":"PLoS ONE"},{"issue":"9","key":"2965_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236277","volume":"15","author":"T Kuragano","year":"2020","unstructured":"Kuragano T. Joki N, Hase H, Kitamura K, Murata T, Fujimoto S et al (2020) Low transferrin saturation (TSAT) and high ferritin levels are significant predictors for cerebrovascular and cardiovascular disease and death in maintenance hemodialysis patients. PLoS ONE 15(9):e0236277","journal-title":"PLoS ONE"},{"issue":"1","key":"2965_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ndt\/gfz192","volume":"36","author":"AA Awan","year":"2021","unstructured":"Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD (2021) Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in non-dialysis-dependent chronic kidney disease. Nephrol Dial Transplant 36(1):129\u2013136","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2965_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1681\/ASN.2006091034","volume":"18","author":"DW Coyne","year":"2007","unstructured":"Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV et al (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18(3):975\u2013984","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2965_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"LA Szczech","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM et al (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74(6):791\u2013798","journal-title":"Kidney Int"},{"issue":"12","key":"2965_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","volume":"363","author":"SD Solomon","year":"2010","unstructured":"Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA et al (2010) Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363(12):1146\u20131155","journal-title":"N Engl J Med"},{"issue":"7","key":"2965_CR25","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1093\/ndt\/gfs007","volume":"27","author":"R Minutolo","year":"2012","unstructured":"Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L et al (2012) Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant 27(7):2880\u20132886","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2965_CR26","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.04601007","volume":"3","author":"RD Kilpatrick","year":"2008","unstructured":"Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M et al (2008) Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3(4):1077\u20131083","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-02965-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:25:53Z","timestamp":1649784353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-02965-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2965"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-02965-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"14 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takahiro Kuragano declares having grants from Chugai Pharmaceutical, Pharmaceutical Company, Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Kyowa Kirin and received a speaker fee from Kyowa Kirin, Fuso Pharmaceutical Industries, Ltd., and Bayer Yakuhin, Ltd. Takahiro Kuragano received an advisory board fee from Astellas Pharma Inc. and Chugai Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the Ethics Review Board of the Hyogo College of Medicine (approval number 419) in accordance with the ethical principles outlined in the 1975 Declaration of Helsinki as revised in 2013.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}